Picture of Hikma Pharmaceuticals logo

HIK Hikma Pharmaceuticals News Story

0.000.00%
gb flag iconLast trade - 00:00
HealthcareBalancedLarge CapNeutral

REG - Hikma Pharmaceutical - Block listing Interim Review





 




RNS Number : 3935O
Hikma Pharmaceuticals Plc
01 October 2019
 

 

Block Listing Six Monthly Return

 

Information provided on this form must be typed or printed electronically and provided to an RIS.

 

LEI: 549300BNS685UXH4JI75

 

Date: 1 October 2019

 

Name of applicant:

Hikma Pharmaceuticals PLC

Name of scheme:

Hikma Pharmaceuticals PLC 2004 Stock Option Plan ("SOP")

&

Hikma Pharmaceuticals PLC 2005 Long-Term Incentive Plan ("LTIP")

&

Hikma Pharmaceuticals PLC 2009 Management Incentive Plan ("MIP")

&

Hikma Pharmaceuticals PLC 2014 Executive Incentive Plan ("EIP")

Period of return

From:

1 April 2019

To:

31 September 2019

Balance of unallotted securities under scheme(s) from previous return:

SOP: 792,700 ordinary shares of 10 pence

LTIP: 102,714 ordinary shares of 10 pence

MIP: 770,393 ordinary shares of 10 pence

EIP: 1,541,128 ordinary shares of 10 pence

Plus:  The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

SOP: 0 ordinary shares of 10 pence

LTIP: 0 ordinary shares of 10 pence

MIP: 0 ordinary shares of 10 pence

EIP: 0 ordinary shares of 10 pence

Less:  Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):

SOP: 0 ordinary shares of 10 pence

LTIP: 0 ordinary shares of 10 pence

MIP: 237,176 ordinary shares of 10 pence

EIP: 429,828 ordinary shares of 10 pence

Equals:  Balance under scheme(s) not yet issued/allotted at end of period:

SOP: 792,700 ordinary shares of 10 pence

LTIP: 102,714 ordinary shares of 10 pence

MIP: 533,217 ordinary shares of 10 pence

EIP: 1,111,300 ordinary shares of 10 pence

         

 

Name of contact:

Peter Speirs

Telephone number of contact:

0207 399 2772

 

Block Listing Six Monthly Return

 

Stock Option Plan ("SOP")

Date

Block Listing

Shares Issued

Balance (Headroom)

Notes

01/10/2019

-

-

792,700

Blocklisting return on 01/10/2019

 

 

 

 

Block Listing Six Monthly Return

 

Long Term Incentive Plan ("LTIP")

Date

Block Listing

Shares Issued

Balance (Headroom)

Notes

01/10/2019

-

-

102,714

Blocklisting return on 01/10/2019

 

Block Listing Six Monthly Return

Management Incentive Plan ("MIP")

Date

Block

Listing

Shares

Issued

 Balance

 (Headroom)

Notes

 

01/04/2019

 

0

0

770,393

Blocklisting return on 01/04/2019

16/04/2019

0

548

769,845

 

09/05/2019

0

1,633

768,212

 

13/05/2019

0

654

767,558

 

16/05/2019

0

1,323

766,235

 

21/05/2019

0

391

765,844

 

23/05/2019

0

919

764,925

 

24/05/2019

0

209,869

555,056

 

30/05/2019

0

2,540

552,516

 

14/06/2019

0

2,713

549,803

 

19/06/2019

0

5,952

543,851

 

03/07/2019

0

418

543,433

 

24/07/2019

0

3,012

540,421

 

09/08/2019

0

664

539,757

 

02/09/2019

0

3,467

536,290

 

09/09/2019

0

1,979

534,311

 

16/09/2019

0

1,094

533,217

 

01/10/2019

0

0

533,217

Blocklisting Return on 01/10/2019

 

 

 

Block Listing Six Monthly Return

 

Executive Incentive Plan ("EIP")

Date

Block Listing

Shares Issued

Balance (Headroom)

Notes

01/04/2019

0

0

1,541,128

Blocklisting return on 01/04/2019

16/04/2019

0

309,686

1,231,442

 

29/04/2019

0

13,666

1,217,776

 

30/04/2019

0

11,803

1,205,973

 

03/05/2019

0

22,241

1,183,732

 

09/05/2019

0

28,818

1,154,914

 

10/05/2019

0

7,524

1,147,390

 

05/06/2019

0

8,629

1,138,761

 

19/06/2019

0

6,538

1,132,223

 

03/07/2019

0

9,729

1,122,494

 

27/09/2019

0

11,194

1,111,300

 

01/10/2019

0

0

1,111,300

Blocklisting return on 01/10//2019

 

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
BLRUGGGGUUPBGCG

Recent news on Hikma Pharmaceuticals

See all news